Our goal is to address our partners’ or the industry’s challenging problems or to pioneer new therapeutic opportunities using our delivery technologies.

We seek collaborations with groups that possess robust domain expertise in relevant therapeutic areas, particularly in current therapeutic needs and strategies. An ideal partner would have a well-established process for in-vitro and in-vivo validation.

Our model involves rapidly designing and generating robust antibody drug candidates and performing preliminary in-vitro evaluations. We then pass these candidates to our partners for more in-depth in-vitro and in-vivo evaluations. The findings are subsequently shared and discussed to determine next steps, which could range from additional research to partnerships with a third party or out-licensing. New intellectual properties generated from the collaboration would be jointly owned.

Initially, we aim to understand your challenges and the current landscape of therapeutic opportunities, focusing on existing strategies and unexplored possibilities. We will then introduce our technologies and provide a general overview of multifunctional therapeutics and their benefits. If we identify opportunities where our delivery technology could solve an existing problem, we propose a collaboration with work plans.

Yes, before a drug can be conjugated to an antibody, it needs to be modified into a prodrug format with a linker, which can then be conjugated to the antibody. Unlike small molecules that are highly cell permeable, antibody-conjugated drugs cannot readily enter cells, except those with specific target receptors.

Yes, before a drug can be conjugated to an antibody, it needs to be modified into a prodrug format with a linker, which can then be conjugated to the antibody. Unlike small molecules that are highly cell permeable, antibody-conjugated drugs cannot readily enter cells, except those with specific target receptors.

Yes, many ADCs in the past have failed due to a narrow therapeutic index. Smart Antibodies can be used to improve the therapeutic index by programming a secondary activation mode into the antibody that is prevalent in the target cells or environment